TRIAL: Treatment of Respiratory Infections with inhaled AntimicrobiaLs
Lead Research Organisation:
University of Oxford
Department Name: Paediatrics
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Publications
Mitsi E
(2024)
RSV and rhinovirus increase pneumococcal carriage acquisition and density, whereas nasal inflammation is associated with bacterial shedding.
in Cell host & microbe
| Description | The team has generated several formulations of nanoparticles which have NO-donors incorporated. These different formulations have been tested on assays that a) assess their capacity to kill a diverse of bacteria (Gram+ and gram-) at different concentrations and b) the effect on cells (both primary human cells and cell lines). We observed that these nanoparticles are more efficient in treating infections caused by Gram negative bacteria than gram positive. In addition, we observed that for encapsulated bacteria, the size of the capsule affects the liposome uptake and subsequently the anti-microbial property. |
| Exploitation Route | The findings generated under this award set up the basis for generating different formulations of particles that have the potential to treat bacterial and viral infections. Taken together the cytotoxicity data and antimicrobial data, the NO-particles will now be tested in animal models to acquire pre-clinical data before we move to human studies. |
| Sectors | Pharmaceuticals and Medical Biotechnology |
| Description | UKHSA Joint Committee on Vaccination and Immunisation (JCVI) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Understanding nasal immunity to improve vaccine protection against respiratory infections |
| Amount | £1,999,711 (GBP) |
| Funding ID | NIHR303129 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2023 |
| End | 10/2028 |
| Description | Oxford Vaccine Group |
| Organisation | University of Oxford |
| Department | Department of Paediatrics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | In 2022 Professor Daniela Ferreira established a joint Institutional research group. Based across Oxford University, Department of Paediatrics and Liverpool School Of Tropical Medicine, Department of Clinical Science's. This partnership will encourage scientific collaboration and enable researchers and students to share expertise and skills to the benefit of both research institutions. |
| Collaborator Contribution | This collaboration with Oxford University has allowed for group members to benefit from increased training , intellectual input and mentoring opportunities. This also includes access to additional facilities and equipment to support research outputs. |
| Impact | Given this institutional collaboration commenced in July 2022. Outputs and outcomes resulting from this collaboration and partnership will be shared in the 2024 annual submission. |
| Start Year | 2022 |
| Description | 13th International Symposium on Pneumococcus and Pneumococcal Disease (ISPPD), Cape Town - Plenary talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 13th International Symposium on Pneumococcus and Pneumococcal Disease (ISPPD), Cape Town - Plenary talk to present the results of large human challenge study with pneumococcus and the effect of current licenced vaccines on the outcome |
| Year(s) Of Engagement Activity | 2024 |
| Description | New York Academy of Medical Sciences, Respiratory Vaccines Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | New York Academy of Medical Sciences, Respiratory Vaccines Meeting |
| Year(s) Of Engagement Activity | 2024 |
| Description | Periscope Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Periscope Meeting, with University Oxford which sparked questions, discussion and collaboration afterwards |
| Year(s) Of Engagement Activity | 2023 |
| Description | TRIAL Scientific Leadership Team |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scientific Leadership group workshop meetings. |
| Year(s) Of Engagement Activity | 2023,2024 |